Fig. 4.

Predicted SRI(4) response at week 52 in all patients and IFNGS-high patients who completed treatment

Data were from the pooled exposure–response analysis set. Two hundred and seventy-six placebo patients (A) and 227 IFNGS-high placebo patients (B) from pooled TULIP trials who completed the treatment were included in the model but are not shown; C_ave was set to 0 μg/ml. C_ave: average serum concentration; IFNGS: type I IFN gene signature; n: number of patients; Obs: observed; SLEDAI-2K: SLE Disease Activity Index 2000; SRI(4): SLE Responder Index ≥4.